Business
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
- XCARTTM continuing to advance toward IND-enabling studies- PolyXen® platform technology growing royalty stream through license agreement- Closed the year
About this update from Xenetic Biosciences, Inc.
[{"type":"text","content":"- XCARTTM continuing to advance toward IND-enabling studies- PolyXen® platform technology growing royalty stream through license agreement- Closed the year with $18.2 million of cashFRAMINGHAM, MA / ACCESSWIRE / March 23, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, today reported its financial results for the full year 2021 and provided a corporate update.\"Over the course of the past year, our team has continued to advance the XCART program through pre-clinical studies, which are key to defining the best development pathway for this novel platform technology. Looking ahead, we remain focused on moving XCART toward IND-enabling studies. Though still early in its development, we believe XCART continues to demonstrate its potential as an important program due to its ability to target cancers with a patient- and tumor-specific approach,\" commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.XCART Platform Technology Overview: Significantly differentiated, proprietary approach to personalized CAR T lymphoma therapy targeting tumor-specific neoantigens that target independently of CD19 or other surface antigens that are common to both normal and malignant B-cells. Lead program for Non-Hodgkin lymphoma, an area of significant unmet need, with the potential to address an initial global market opportunity of over $7 billion annually.[1]Program Highlights:Advancing preclinical efforts through ongoing research and development collaborations including with The Scripps Research Institute and other institutions in the United States (\"U.S.\") covering design and implementation of the pre-clinical development program, as well as activities supporting process development for clinical manufacturing.Bolstered intellectual property portfolio with issuance of a U.S. patent covering the co-administration of XCART-derived CAR T cells, together with a personalized vaccine designed to enhance the effectiveness of the CAR T therapy.PolyXen Platform Technology: Patent-protected platform technology designed for protein or peptide therapeutics, enabling next-generation biological drugs by prolonging a drug's circulating half-life and potentially impro...